Payments for License Fees

No definition available.

Name:	opht_PaymentsforLicenseFees
Namespace Prefix:	opht_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the amount of patient enrollment-based milestone revenue achieved by the entity.

+ References

No definition available.

+ Details

Name:	opht_ResearchAndDevelopmentArrangementAmountOfEnrollmentBasedMilestoneAchieved
Namespace Prefix:	opht_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the amount of upfront fees received under the agreement.

+ References

No definition available.

+ Details

Name:	opht_ResearchAndDevelopmentArrangementUpfrontFeesReceived
Namespace Prefix:	opht_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Aggregate revenue during the period from services rendered in the normal course of business, after deducting allowances and discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(d))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

+ Details

Name:	us-gaap_SalesRevenueServicesNet
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_CounterpartyNameAxis=opht_NovartisPharmaAGMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=opht_LicensingAndCommercializationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	opht_MilestoneEventsAxis=opht_AchievementOfSpecifiedPatientEnrollmentMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=opht_UniversityofFloridaResearchFoundationUFRFMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=opht_RHOadRPLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	opht_MilestoneEventsAxis=opht_SpecifiedClinicalMarketingApprovalandReimbursementApprovalMilestonesRelatedtoaLicensedProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	opht_MilestoneEventsAxis=opht_SpecifiedCommercialSalesMilestonesRelatedtoaLicensedProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Licensing and Commercialization Agreements - Narrative (Details) - USD ($) $ in Thousands	1 Months Ended							3 Months Ended			6 Months Ended		22 Months Ended
	Jun. 30, 2018	Aug. 31, 2017	Jul. 31, 2017	Jun. 30, 2016	Mar. 31, 2015	Sep. 30, 2014	May 31, 2014	Jun. 30, 2018	Sep. 30, 2017	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Upfront fees received		$ 16,900
Total collaboration revenue								$ 0	$ 206,700	$ 1,661	$ 0	$ 3,323
Novartis Pharma AG \| Licensing and Commercialization Agreement
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Upfront fees received			$ 189,800				$ 200,000
Achievement of specified patient enrollment milestones \| Novartis Pharma AG \| Licensing and Commercialization Agreement
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Patient enrollment-based milestone revenue achieved				$ 30,000	$ 50,000	$ 50,000							$ 130,000
Research and development \| University of Florida Research Foundation (UFRF) \| RHO-adRP License Agreement
Research and Development Arrangement, Contract to Perform for Others [Line Items]
License fees paid	$ 500
Research and development \| Specified clinical, marketing approval and reimbursement approval milestones with respect to a licensed product \| University of Florida Research Foundation (UFRF) \| RHO-adRP License Agreement
Research and Development Arrangement, Contract to Perform for Others [Line Items]
License fees paid	23,500
Research and development \| Specified commercial sales milestones with respect to a licensed product \| University of Florida Research Foundation (UFRF) \| RHO-adRP License Agreement
Research and Development Arrangement, Contract to Perform for Others [Line Items]
License fees paid	70,000
General and administrative \| University of Florida Research Foundation (UFRF) \| RHO-adRP License Agreement
Research and Development Arrangement, Contract to Perform for Others [Line Items]
License fees paid	$ 30